<DOC>
	<DOCNO>NCT02681952</DOCNO>
	<brief_summary>A Multicenter , Randomized , Open-labeled , Cross-over , Active-controlled , Phase IV Clinical Trial Evaluate Preference Formulation Efficacy Safety Renamezin Kremezin Pre-dialysis Patients With Chronic Renal Failure</brief_summary>
	<brief_title>A Multicenter , Randomized , Open-labeled , Cross-over , Active-controlled , Phase IV Clinical Trial Evaluate Preference Formulation Efficacy Safety Renamezin Kremezin Pre-dialysis Patients With Chronic Renal Failure</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>predialysis patient chronic renal failure stage patient hold stable state serum creatinine 2.0mg/dl 5.0mg/dl MDRD GFR 1560ml/min/1.73m2 3 month screen patient n't experience dose spherical carbon adsorbent 3months screening patient noticeable change 4weeks screening expect change need therapy therapy chronic renal failure ( type blood pressure medication dose relate , diet therapy ) patient spontaneously write consent participate clinical trial patient pass digestive tract disorder patient uncontrolled constipation symptom kidney transplant patient patient take immunosuppressive drug patient suffer digestive tract ulcer esophageal varix patient uncontrolled hypertension patient hospitalize cardiovascular disease within 3 month screen patient current infection patient fulfill therapy chronic renal failure ( take medicine diet ) appropriate patient hepatic impairment ( 2.5 time great upper limit normal level AST , ALT ) uncontrolled diabetes ( HbA1c &gt; 10 % fast glucose &gt; 180mg / dL ) patient malignant tumor ( However , relapse within five year completion therapy register ) pregnant woman , nurse mother agree contraceptive method allow possibility pregnancy woman patient participate another clinical trial addition current clinical trial subject dependency drug alcohol subject take investigational drug within 30 day participate clinical trial study patient expect start dialysis within three month patient deem unsuitable tester</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>